August 3, 2005

Encision Welcomes Enactment of Patient Safety Act of 2005

Boulder, Colorado, August 3, 2005 -- Encision Inc. (Amex: ECI), a medical device company with patented surgical technology emerging as a standard of care in minimally-invasive surgery, welcomes the enactment of the Patient Safety and Quality Improvement Act of 2005. This federal patient safety legislation, signed by President George W. Bush, will encourage the voluntary reporting of medical errors, serious adverse events and their underlying causes.

A White House Press Release on July 29, 2005 stated, “To maintain the highest standards of care, doctors and nurses must be able to exchange information about problems and solutions. Yet in recent years, many doctors have grown afraid to discuss their practices because they worry that the information they provide will be used against them in a lawsuit. This bill will help solve that problem.”

“We are pleased that Congress has passed this legislation to help remove the veil of silence surrounding surgical and medical injuries that can be prevented by patient safety solutions like active electrode monitoring,” said Jack Serino, President and CEO of Encision. “Encision’s AEM® technology is a fail-safe system to prevent stray energy burns from instrument insulation failure and capacitive coupling in patients undergoing laparoscopic surgery. As the true incidence of stray energy burns, which may currently be widely underreported, becomes better understood, we expect that the decision to adopt AEM technology in operating rooms will become more compelling.”

Encision Inc. designs and manufactures innovative surgical devices that allow the surgeon to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase revenues through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission.

CONTACT: Marcia McHaffie, Encision Inc., 303-444-2600, mmchaffie@encision.com